NERVGEN PHARMA CORP

NGENNASDAQ

Earnings Aug 21US Equity

$1.76▲ $0.02 (+0.86%)

Live

1h—

24h▲ 0.9%

7d▲ 4.2%

14d▲ 11.1%

30d▼ 8.8%

1y—

🏦Market Cap

$186M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Fair

Trading Snapshot

Day Range: $1.74 – $1.77
52-Week Range: —
Volume: $4.74B
Avg Volume: $4.31B
Shares Outstanding: 106.2M
Next Earnings: Sep 4, 2026

Fundamentals Snapshot

Annual Revenue: $20M
Last Q Revenue: $5M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): —
Dividend Yield: —

Why Investors Own NGEN

✓High-growth profile — revenue up +1.4% YoY with expanding US Equity exposure.
✓Healthy economics — 78% gross margin and 24% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$20M▲ +0.0% YoY

Gross Margin (TTM)

78.0%▲ +4.5% YoY

Operating Income (TTM)

$2M▲ +0.0% YoY

Free Cash Flow (TTM)

$5M▲ +0.0% YoY

About NERVGEN PHARMA CORP

NervGen Pharma Corp. is a biotechnology enterprise currently in its clinical development phase, focused on devising therapeutic solutions for nerve injuries and progressive neurodegenerative diseases. Their innovative approach centers on deactivating the natural biological mechanisms that typically impede the nervous system's ability to repair itself.

🦦